US Payer Perspectives on Evidence for Formulary Decision Making
- 1 May 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 8 (3S) , 22s-27s
Abstract
To improve formulary design processes and support payers in providing more effective health care, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.Keywords
This publication has 8 references indexed in Scilit:
- Challenges Facing the US Patient-Centered Outcomes Research Institute2011
- Real-world Imperative of Outcomes ResearchJAMA, 2011
- Developing the Sentinel System — A National Resource for Evidence DevelopmentNew England Journal of Medicine, 2011
- Optimizing health information technology's role in enabling comparative effectiveness research.2010
- How Best To Engage Patients, Doctors, And Other Stakeholders In Designing Comparative Effectiveness StudiesHealth Affairs, 2010
- Managed care & medical oncology: the focus is on value.Journal of the National Comprehensive Cancer Network, 2010
- What outcomes should US policy makers compare in comparative effectiveness research?Expert Review of Pharmacoeconomics & Outcomes Research, 2010
- Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payersNature Reviews Drug Discovery, 2010